Abstract
Personalized medicine tailors treatment to meet an individual patient's needs and specific disease. While the idea of personalized medicine is not new, advances in biomedical science have evolved to target molecular pathways to reduce toxicity and provide more effective treatment options to patients with many common cancers. For a few cancers, such as breast cancer, biomarker assisted diagnoses and therapy have already replaced the standard “one size fits all” treatment. As our understanding of molecular genetics increases we will be able to offer tailored cancer therapy to more patients, however, the cost of cancer care will continue to be a public policy concern. In this session we will discuss the promise and pitfalls of personalized medicine from a clinical science perspective.
Citation Format: Nefertiti C. duPont{Authors}. Promise and pitfalls of personalized medicine from a clinical science perspective. [abstract]. In: Proceedings of the Sixth AACR Conference: The Science of Cancer Health Disparities; Dec 6–9, 2013; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2014;23(11 Suppl):Abstract nr SS03-01. doi:10.1158/1538-7755.DISP13-SS03-01